Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

157.60GBp
28 Mar 2017
Change (% chg)

1.20 (+0.77%)
Prev Close
156.40
Open
156.30
Day's High
159.50
Day's Low
153.50
Volume
1,986,955
Avg. Vol
1,752,976
52-wk High
179.00
52-wk Low
122.90

VEC.L

Chart for VEC.L

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.72
Market Cap(Mil.): £1,060.35
Shares Outstanding(Mil.): 677.98
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 29.25 30.03
EPS (TTM): -- -- --
ROI: -- 13.69 13.19
ROE: -- 14.58 14.33

BRIEF-Vectura posts 9-month loss before taxation of 40.1 million stg

* Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016

21 Mar 2017

BRIEF-Vectura achieves 9 mln stg royalty cap from GSK's Ellipta

* Achieves £9 million royalty cap from gsk ellipta ® products Source text for Eikon: Further company coverage: (Reporting By London Bureau)

16 Feb 2017

BRIEF-Vectura gets $5 mln after an inhaling device hits sales milestone

* Seebri/Ultibro Breezhaler 2016 sales reach $512 mln triggering $5 mln milestone receipt Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

25 Jan 2017

BRIEF-Vectura says U.S. FDA approves IND for paediatric asthma trial

* Fda approves IND to support Vectura's wholly-owned programme VR647 in paediatric asthma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

24 Jan 2017

BRIEF-Vectura's first-half pretax loss widens to 18.6 million

* H1 pretax loss -18.6 million stg versus -2.7 million stg loss year ago Source text for Eikon: Further company coverage: (Reporting By London Bureau)

23 Nov 2016

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

22 Nov 2016

Vectura on lookout for deals to build specialized lung drug business

LONDON James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal.

01 Nov 2016

More From Around the Web

Earnings vs. Estimates